Tuberculosis Treatment Monitoring
Cross-source consensus on Tuberculosis Treatment Monitoring from 1 sources and 5 claims.
1 sources · 5 claims
Uses
How it works
Risks & contraindications
Other
Highlighted claims
- WHO recommends sputum culture and AFB smear microscopy to monitor treatment response in pulmonary TB. — Evaluating the PATHFAST TB LAM Ag assay as a treatment monitoring tool for pulmonary tuberculosis: protocol for a prospective longitudinal study in Nairobi, Kenya
- The WHO target product profile for TB treatment monitoring tools requires minimum acceptable performance targets of sensitivity ≥75% and specificity ≥80% with feasibility in resource-limited settings. — Evaluating the PATHFAST TB LAM Ag assay as a treatment monitoring tool for pulmonary tuberculosis: protocol for a prospective longitudinal study in Nairobi, Kenya
- The optimal LAM-change cut-off is selected using a combination of the Youden Index, a clinically acceptable false-negative rate, and alignment with WHO TPP targets. — Evaluating the PATHFAST TB LAM Ag assay as a treatment monitoring tool for pulmonary tuberculosis: protocol for a prospective longitudinal study in Nairobi, Kenya
- Treatment failure leads not only to poor patient outcomes but also to the emergence and spread of drug-resistant TB. — Evaluating the PATHFAST TB LAM Ag assay as a treatment monitoring tool for pulmonary tuberculosis: protocol for a prospective longitudinal study in Nairobi, Kenya
- TB treatment failure is driven by long therapy duration and adherence difficulties. — Evaluating the PATHFAST TB LAM Ag assay as a treatment monitoring tool for pulmonary tuberculosis: protocol for a prospective longitudinal study in Nairobi, Kenya